MonTa Biosciences is an immuno-oncology company with our main asset being a TLR7 formulation.
We have demonstrated antitumor activity in monotherapy and combination with immune checkpoint inhibitors, radiotherapy and chemotherapy. We are in the development phase with ongoing CMC activity and toxicology studies and expect to initiate phase I by Q1 2021.